GDTC: w2.cytomed.sg Company Value to Net Income
CytoMed Therapeutics (GDTC) is accelerating preclinical trials through robotic compound screening, which is critical for NK-cell survival and scaling production in Singapore. Market price action on GURU.Markets for the separate_pe metric currently stands at -3.70. The Singapore-based cell therapy developer is not yet profitable, relying instead on the success of current tests and future regulatory approvals to bring its drugs to market.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_GDTC_-_CytoMed-Therapeutics_-_PE-Multiple "GDTC: CytoMed Therapeutics Price to Earnings Ratio 02/21/2024 - 11/12/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for CytoMed Therapeutics Ltd (GDTC)
- share price and expert price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
All Debt to Shareholders' Equity Ratio CytoMed Therapeutics|GDTC - Long-Term Debt to Capital|Current Liabilities to Capital CytoMed|GDTC - Company Aggregate Debts|Debt to Book Value CytoMed Therapeutics Limited|GDTC - Company Long-Term Liabilities|Short-Term Debt CytoMed Therapeutics|Intermediate Liquidity Ratio w2.cytomed.sg
- company profitability and valuation multiples indicators:
GDTC - Company Net Income|Expected Net Profit CytoMed Therapeutics|GDTC - Price to Earnings Ratio|Projected Price to Earnings CytoMed|GDTC - PEG Multiple|Company Value to EBITDA CytoMed Therapeutics Limited|GDTC - Operating profit EBITDA|Earnings per share for the last 12 months CytoMed Therapeutics|GDTC - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months w2.cytomed.sg|GDTC - Net earnings per share growth this year|Projected earnings per share increase next year CytoMed Therapeutics
Summary company analysis:GDTC w2.cytomed.sg
Market expectations for CytoMed Therapeutics (GDTC) often outpace current earnings due to the high cost of developing T-cell therapies and stringent FDA oversight. By analyzing the company's annual P/E ratio, an investor assesses the relationship between market capitalization and net income, which helps determine the premium paid for exclusive patents and the business's lobbying potential in Asia.
Competing companies
ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Company Value to Net Income|P/E Multiple AAPG (Ascentage)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis (PSNL) - Price to Earnings Ratio|Erasca Inc - Company Value to Net Income|DCTH (Delcath) - P/E Multiple|Market Cap to Earnings Y-mAbs Corp YMAB|P/E Multiple AURA|Price to Earnings Ratio candeltx.com CADL|Accuray - Price to Earnings Ratio|SELLAS Life Sciences Group, Inc. (SLS) - Market Cap to Earnings|ACTU: Price to Earnings Ratio|Citius Oncology Inc - Market Price to Net Income Ratio|tuhurabio.com (HURA) - Price to Earnings Ratio|Market Cap to Earnings protaratx.com (TARA)|Price to Earnings Ratio Fate Therapeutics|Price to Earnings Ratio Aadi Bio (WHWK)|P/E Multiple TCRX|CSBR - Market Cap to Earnings|P/E Multiple XBIT (XBiotech)|CVM: Price to Earnings Multiple|OSTX: Price to Earnings Ratio|Company Value to Net Income RADX (radiopharmtheranostics.com)|ARTV (artivabio.com) - Price to Earnings Ratio|ANL: Market Price to Net Income Ratio|VERU (Veru Inc.) - P/E Multiple|TPST: Company Value to Net Income|P/E Multiple XLO|RENB - Market Cap to Earnings|Price to Earnings Ratio Mural Oncology MURA|Company Value to Net Income KAPA|OnKure - P/E Multiple|CRIS - P/E Multiple|apollomicsinc.com (APLM) - Price to Earnings Ratio|Market Cap to Net Income THAR (Tharimmune Inc)|ADVB (Advanced Biomed Inc.) - P/E Multiple|Market Cap to Earnings Genprex Inc GNPX|Price to Earnings Ratio CLDI (Calidi Biotherapeutics)|P/E Multiple sunshinebiopharma.com (SBFM)|Xenetic Biosciences, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio SLRX (Salarius Pharmaceuticals Inc)|Purple Biotech Corp - P/E Multiple|Business Payback Period American Oncology Network AONC|BGNE: P/E Multiple|Price to Earnings Ratio checkpointtx.com|Price to Earnings Ratio Elevation Oncology|iCAD Corp (ICAD) - Business Payback Period|P/E Multiple IKNA|Notable Labs Corp (NTBL) - Market Cap to Net Income Ratio|P/E Multiple VIRX (Viracta Therapeutics, Inc.)|MOR: Price to Earnings Multiple|NAYA: Price to Earnings Ratio|Ascentage Pharma Group International - Market Price to Net Income Ratio
